Media Coverage

Quest Diagnostics and Oxford Immunotec announced that Quest has completed its acquisition of the U.S. laboratory services business of Oxford Immunotec; the T-Spot.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest’s portfolio of infectious disease testing services.

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 37th Annual J. P. Morgan Healthcare Conference in San Francisco. Stephen Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 8, 2019 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A session moderated by the host analyst.

The Centers for Disease Control and Prevention (CDC) reported that more than 70,000 people in the United States died of drug overdoses in 2017. That devastating number broke records as the highest number for any single year in our country’s history and contributed to a decrease in life expectancy. Today drug overdoses rank as the leading cause of death for adults under age 55. DownloadQuest Diagnostics white paper about how the opioid crisis affects the workplace.

UBS initiated coverage of Quest Diagnostics and Laboratory Corporation of America on Thursday with a Neutral and Buy rating, respectively. In a report, analyst Kevin Caliendo put a a 12-month price target in Quest's shares of $90 and wrote that while he believes Quest could take market share from LabCorp and other competing reference labs, his analysis of Quest's long-term strategic partnership with UnitedHealthcare, announced in May, "suggests less switching to Quest than is expected."

A recent press release by Quest Diagnostics released new research showing that majority of adults don't know their vital health information, but would like to be able to access their health information online.

The rate of positive drug tests rose by double digits in five of 16 major U.S. workforce industry sectors from 2015 to 2017, according to a recent analysis by lab services provider Quest Diagnostics.

Patient health literacy and knowledge about their own medical information leaves a lot to be desired, leading to calls for better patient education about patient portal and data access, according to a survey conducted by Kelton Global on behalf of Quest Diagnostics.

The rate of positive drug tests rose by double digits in five of 16 major U.S. workforce industry sectors from 2015 to 2017, according to a recent analysis by lab services provider Quest Diagnostics. An examination of data from more than 10 million urine drug tests conducted over the three-year period showed that transportation and warehousing had the largest increase, at 21.4 percent, followed by other services except public administration (15.4 percent), finance and insurance (13), retail trade (12.8), and wholesale trade (11.8).

With trends in drug misuse shifting, Quest Diagnostics is using data mining to help clinicians stay on top of the problem. Quest annually mines and analyzes data from millions of drug tests performed at its laboratories across the country. Last fall, the company released its annual Health Trends, Drug Misuse in America 2018 report, based on 3.9 million de-identified, aggregated lab tests conducted at the Quest laboratories between 2011 and 2017. The mining exercise, and the resulting annual report, are intended to serve as a guide for the clinicians it serves, and for its own laboratories looking to better prepare to meet drug testing needs.

Beginning Jan. 1, 2019, employees and their families who have enrolled with Penn State health benefits will pay the least amount of coinsurance (10 percent), after their deductible, for lab services by using Quest Diagnostics or LabCorp.